CHICAGO -- An investigational dual-action inhibitor for geographic atrophy (GA) significantly slowed disease progression and ...

PYC Therapeutics Limited (AU:PYC) has released an update. PYC Therapeutics has dosed its first patient in a clinical trial for its innovative ...

Alkeus Pharmaceuticals’ study results from Gildeuretinol shows significant trend in slowing geographic atrophy: Cambridge, Massachusetts Friday, October 25, 2024, 10:00 Hrs [IST ...

Astellas has announced the withdrawal of its MAA for ACP from the EMA to treat geographic atrophy (GA) secondary to AMD.

The annual meeting of the American Academy of Ophthalmology was held from Oct. 18 to 21 in Chicago and attracted participants ...

While AMD doesn't typically cause complete blindness, it severely impairs vision in the center of the eye, making everyday activities like reading and recognizing faces difficult. There are two main ...

Astellas to withdraw European marketing authorization application for avacincaptad pegol to treat GA secondary to AMD: Tokyo Tuesday, October 29, 2024, 13:00 Hrs [IST] Astellas Ph ...

S cience Corporation, a rival to Elon Musk’s Neuralink in the development of brain-computer interface (BCI) technology, has just unveiled promising early clinical trial results for an eye implant that ...

While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA ... Medicines Agency (EMA), to bring the treatment to patients with GA. The detour for Izervay ...

Born in 1991, I was the third child but the second living. My sister, Lindsay, passed away at six months old from a ...

NIDO-361, a treatment for spinal and bulbar muscular atrophy (SBMA) now in a Phase 2 trial, was granted orphan drug ...